Table 2.
Exercise performance variables at anaerobic threshold and during exercise after administration of pyridostigmine and placebo
| Pyridostigmine | Placebo | |
| HR at AT (beats/min) | 103 (5) | 104 (4) |
| HR at peak exercise (beats/min) | 129 (5) | 129 (5) |
| V̇o2 at AT (ml/kg/min) | 12.2 (1.1) | 11.6 (1.1) |
| V̇o2 at peak exercise (ml/kg/min) | 17.7 (1.5) | 17.4 (1.5) |
| RER at peak exercise | 1.05 (0.01) | 1.04 (0.02) |
| Exercise V̇E–V̇co2 slope | 34.2 (1.8) | 33.7 (1.6) |
| V̇E–V̇co2 slope at AT | 38.8 (1.8) | 37.6 (2.0) |
| MAP at peak exercise (mm Hg) | 98 (2) | 100 (2) |
All values expressed as mean (SEM).
AT, anaerobic threshold; HR, heart rate; MAP, mean arterial pressure; RER, respiratory exchange ratio; V̇o2, oxygen consumption.